Aerie Pharmaceuticals
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch AERI and buy or sell other stocks, ETFs, and their options commission-free!About AERI
Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105.
CEODavid J. Endicott, MBA
CEODavid J. Endicott, MBA
Employees—
Employees—
HeadquartersDurham, North Carolina
HeadquartersDurham, North Carolina
Founded2005
Founded2005
Employees—
Employees—
AERI Key Statistics
Market cap753.62M
Market cap753.62M
Price-Earnings ratio-19.89
Price-Earnings ratio-19.89
Dividend yield—
Dividend yield—
Average volume515.67K
Average volume515.67K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$15.37
52 Week high$15.37
52 Week low$4.81
52 Week low$4.81
Stock Snapshot
The current Aerie Pharmaceuticals(AERI) stock price is $15.25, with a market capitalization of 753.62M. The stock trades at a price-to-earnings (P/E) ratio of -19.89.
On 2025-12-12, Aerie Pharmaceuticals(AERI) stock opened at —, reached a high of —, and a low of —.
The Aerie Pharmaceuticals(AERI)'s current trading volume is 0, compared to an average daily volume of 515.67K.
During the past year, Aerie Pharmaceuticals(AERI) stock moved between $4.81 at its lowest and $15.37 at its peak.
During the past year, Aerie Pharmaceuticals(AERI) stock moved between $4.81 at its lowest and $15.37 at its peak.
People also own
Based on the portfolios of people who own AERI. This list is generated using Robinhood data, and it’s not a recommendation.